Innate Pharma
Created in 1999
Up & running (A)
Existing signals show a regular activitySocial networks
4,094 27,354Activities
Technologies
Entity types
Location
117 Av. de Luminy, 13009 Marseille, France
Marseille
France
Employees
Scale: 201-500
Estimated: 196
SIREN
424365336Engaged catalyst
26
0 0Added in Motherbase
5 years, 2 months ago
Value proposition
Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
Innate has been a pioneer in the understanding of natural killer cell (NK cell) biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.
Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
biotechnologies, antibodies, immunotherapy, and oncologyOriginal language
Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
Innate has been a pioneer in the understanding of natural killer cell (NK cell) biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.
Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Welcome to Innate Pharma | Innate Pharma
https://www.innate-pharma.com/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 Europe 1 Broadcast Media Production and Distribution | Europe 1 Broadcast Media Production and Distribution | Other 5 Feb 2025 | | |
 Maison du doctorat - Université Paris-Saclay Research, Higher Education | Maison du doctorat - Université Paris-Saclay Research, Higher Education | Other 30 Jan 2025 | | |
 J.P. Morgan Bank | J.P. Morgan Bank | Other 10 Jan 2025 | | |
 CMS Francis Lefebvre Avocats Law Practice | CMS Francis Lefebvre Avocats Law Practice | Other 29 Dec 2024 | | |
 Morgan Stanley Finance, Bank | Morgan Stanley Finance, Bank | Other 6 Sep 2023 | | |
 Gustave Roussy Health, Hospitals and Health Care | Gustave Roussy Health, Hospitals and Health Care | Other 12 Feb 2025 | | |
 L'Oréal Cosmetics, Personal Care Product Manufacturing | L'Oréal Cosmetics, Personal Care Product Manufacturing | Other 4 Dec 2023 | | |
 Takeda Pharmaceutical, Pharmaceutical Manufacturing | Takeda Pharmaceutical, Pharmaceutical Manufacturing | Other 4 Apr 2023 | | |
 Tech Nation Software Development | Tech Nation Software Development | Other 31 Jul 2022 | | |
 La French Tech Aix-Marseille Région Sud French Tech, Software Development | La French Tech Aix-Marseille Région Sud French Tech, Software Development | Other 26 Mar 2019 | | |
👨💻 Replay of our Full Year 2024 Financial Results and Business Update conference call 📊
In case you missed it, the replay of the presentation and the Q&A session is now available: https://lnkd.in/eG7epxzt
#InnatePharma #FullYearResults #Finance
Innate Pharma reports its Full Year 2024 Financial Results and Business Update 💊📈
To find our more, you can take part in our conference call, to be held today at 2:00 p.m. CET / 9:00 a.m. EDT.
All information in our press release: https://lnkd.in/d3zsuKDX
#InnatePharma #Biotech #Bourse #FullYearResults
Meet us at the AACR 2025 🔬🧑🏫
We are proud to highlight the antibody drug conjugate IPH4502 abstract selected for the AACR 2025 Annual Meeting.
💊 IPH4502 is a novel and differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors.
💊 IPH4502 demonstrated preclinical anti-tumor efficacy in models of primary and acquired resistance to enfortumab vedotin and in tumors with low to moderate levels of Necton-4 expression, extending its potential beyond urothelial carcinoma.
📢 In addition, Jonathan Dickinson, CEO of Innate will present in a Showcase Session at the AACR Oncology Industry Partnering Event.
For more info, read the press release: https://lnkd.in/eUUEpqMY
#InnatePharma #Immunotherapy #Abstract #AACR2025 American Association for Cancer Research
#MeetInnate
Come and meet members of our management team at the Life Sciences Van Lanschot Kempen Conference being held on April 1-3, 2025 in Amsterdam, Netherlands. 📍
We look forward to meeting you and presenting our innovative products.
More info: https://lnkd.in/eaZFHGix
#InnatePharma #IRmeeting #Immunotherapy
Conference call and webcast for our Full Year 2024 Financial Results 📢📊
We are pleased to host a conference call on the occasion of the release of our 2024 financial results.
👥 Participants during the call will be:
• Jonathan Dickinson, Chief Executive Officer
• Sonia Quaratino, Executive Vice President, Chief Medical Officer
• Yannis Morel, Executive Vice President, Chief Operating Officer
• Frédéric LOMBARD, Senior Vice President, Chief Financial Officer
The live webcast will be available at the following link 👉 https://lnkd.in/eG7epxzt
#InnatePharma #Finance #FullYearResults #Webinar